Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does IVOSIDENIB Cause Product administration interrupted? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Product administration interrupted have been filed in association with IVOSIDENIB (TIBSOVO). This represents 0.4% of all adverse event reports for IVOSIDENIB.

7
Reports of Product administration interrupted with IVOSIDENIB
0.4%
of all IVOSIDENIB reports
1
Deaths
2
Hospitalizations

How Dangerous Is Product administration interrupted From IVOSIDENIB?

Of the 7 reports, 1 (14.3%) resulted in death, 2 (28.6%) required hospitalization.

Is Product administration interrupted Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for IVOSIDENIB. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does IVOSIDENIB Cause?

Off label use (613) Fatigue (144) Diarrhoea (100) Nausea (100) Disease progression (86) Differentiation syndrome (80) Product dose omission issue (68) Drug ineffective (64) Platelet count decreased (61) Electrocardiogram qt prolonged (58)

What Other Drugs Cause Product administration interrupted?

CALCIUM OXYBATE\MAGNESIUM OXYBATE\POTASSIUM OXYBATE\SODIUM OXYBATE (1,446) SODIUM OXYBATE (1,272) CANNABIDIOL (511) ISOTRETINOIN (503) APREMILAST (314) TREPROSTINIL (295) EPOPROSTENOL (205) LENALIDOMIDE (146) ETANERCEPT (142) INTERFERON BETA-1A (115)

Which IVOSIDENIB Alternatives Have Lower Product administration interrupted Risk?

IVOSIDENIB vs IXABEPILONE IVOSIDENIB vs IXAZOMIB IVOSIDENIB vs IXEKIZUMAB IVOSIDENIB vs JAKAFI IVOSIDENIB vs JAKAVI

Related Pages

IVOSIDENIB Full Profile All Product administration interrupted Reports All Drugs Causing Product administration interrupted IVOSIDENIB Demographics